RxSight, Inc.

NASDAQ:RXST

Medical - Devices

Healthcare
$5.01 +0.98%

+$0.05 today

Market cap
$210.07M
Beta
1.13
P/E (TTM)
-4.1
EPS (TTM)
-$1.13
52W Low $4.48High $14.29

Volume 0.74M

Average 0.80M

RXST Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

RxSight, Inc.NASDAQ: RXST

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 41.31M shares rose 2.0% year over year, behind the +3.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +14.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.0% toward the trailing-twelve-month pace of +3.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
41.31M+0.3% QoQ
Last fiscal yearDec 2025
41.18M+5.9% YoY
LTMMar 2026
41.05M+3.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.0%——
1 year+5.9%——
3-year CAGR+14.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
41.18M USD
Year-over-year change
+5.9%
4-year CAGR
+10.8%

Weighted Avg Shares vs competitors

How RXST compares with its peers on the latest reported figures

  • RXST's LTM Mar 2026 weighted avg shares of 41.05M shares is the 5th highest of the 9 companies compared; the peer median is 42.25M shares.
  • Its year-over-year change of +3.2% is the 6th highest of 9, against a peer median of +7.2%.
  • Over three fiscal years its annual growth of +14.2% compares with a peer median of +6.0%.
RXST Competitors Peer median
Weighted Avg Shares for RXST and competitors
Company Period LTM YoY 3-year CAGR
BFLYButterfly Network, Inc.LTM Mar 2026250.79M +15.2%+7.3%
CERSCerus CorporationLTM Mar 2026192.35M +3.7%+2.6%
TMCITreace Medical Concepts, Inc.LTM Mar 202663.74M +2.3%+4.6%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
RXSTRxSight, Inc.LTM Mar 202641.05M +3.2%+14.2%
DCTHDelcath Systems, Inc.LTM Mar 202636.16M +16.9%+59.3%
NPCENeuroPace, Inc.LTM Mar 202633.11M +10.6%+10.0%
KIDSOrthoPediatrics Corp.LTM Mar 202623.51M +1.4%+4.3%
TCMDTactile Systems Technology, Inc.LTM Mar 202622.71M -4.9%+4.5%
Peer median (excluding RXST) 42.25M+7.2%+6.0%

Competitors are the stored peer set for RXST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue22.59M49.01M89.08M139.93M134.48M
Cost of Revenue18.08M27.68M35.31M40.98M31.47M
Gross Profit4.52M21.33M53.77M98.94M103.01M
Gross Margin20.0%43.5%60.4%70.7%76.6%
Research & Development24.5M25.98M29.05M34.37M38.55M
Selling, General & Admin32.81M58.67M74.8M101.43M112.65M
Operating Expenses57.3M84.65M103.85M135.8M151.2M
Depreciation & Amortization3.99M4.02M4.24M3.62M0
EBITDA(41.01M)(57.78M)(41.04M)(23.76M)(38.84M)
EBITDA Margin-181.5%-117.9%-46.1%-17.0%-28.9%
Operating Income(52.79M)(63.32M)(50.09M)(36.86M)(48.19M)
Operating Margin-233.6%-129.2%-56.2%-26.3%-35.8%
Interest Income54K1.52M6.57M9.47M2.51M
Interest Expense3.68M4.95M3.31M21K40K
Other Income / Expenses4.11M(3.43M)1.5M9.45M9.31M
Income Before Tax(48.68M)(66.75M)(48.59M)(27.41M)(38.88M)
Pre-Tax Margin-215.5%-136.2%-54.5%-19.6%-28.9%
Income Tax Expense8K9K20K50K66K
Net Income(48.69M)(66.76M)(48.61M)(27.46M)(38.94M)
Net Margin-215.5%-136.2%-54.6%-19.6%-29.0%
EPS (Basic)(1.78)(2.41)(1.41)(0.71)(0.95)
EPS (Diluted)(1.78)(2.41)(1.41)(0.71)(0.95)
Weighted Avg Shares27.37M27.66M34.46M38.87M41.18M
Weighted Avg Shares (Diluted)27.37M27.66M34.46M38.87M41.18M

RxSight, Inc.

NASDAQ:RXST

Intrinsic Alpha fair value

Locked

Current Price

$5.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.